AER-271 | CAS#634913-39-6 | AQP4 inhibitor

AER-271
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555644

CAS#: 634913-39-6

Description: AER-271 is a potent aquaporin-4 ( AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Treatment with AER-271 ameliorated early cerebral edema measured at 3 h after CA vs vehicle treated rats. This treatment also attenuated early NDS. In contrast to rats treated with vehicle after CA, rats treated with AER-271 did not develop significant neuronal death or neuroinflammation as compared to sham.

Chemical Structure

AER-271

CAS# 634913-39-6

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 555644
Name: AER-271
CAS#: 634913-39-6
Chemical Formula: C15H9ClF6NO5P
Exact Mass: 462.98
Molecular Weight: 463.653
Elemental Analysis: C, 38.86; H, 1.96; Cl, 7.65; F, 24.59; N, 3.02; O, 17.25; P, 6.68

Price and Availability

Size	Price	Availability
50mg	USD 550	2 Weeks
100mg	USD 950	2 Weeks
200mg	USD 1650	2 Weeks
500mg	USD 2850	2 Weeks
1g	USD 3850	2 Weeks
2g	USD 6250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: AER-271; AER 271; AER271;

IUPAC/Chemical Name: 2-{[3,5-Bis(trifluoromethyl) phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate

InChi Key: WSHXPHFIHYXZKC-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H9ClF6NO5P/c16-9-1-2-12(28-29(25,26)27)11(6-9)13(24)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6H,(H,23,24)(H2,25,26,27)

SMILES Code: O=P(O)(OC1=CC=C(Cl)C=C1C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	AER-271, a phosphonate prodrug derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor.
In vitro activity:	TBD
In vivo activity:	At 3 h post-CA %BW was increased in CA-vehicle-treated vs. naive rats (83.84 [83.16, 83.39]) vs. 83.17 [82.68, 83.28] respectively, p<0.05) (Figure 2a). AER-271 treatment prevented the acute increase in %BW (83.29 [83.16, 83.39], CA-AER-271 vs naïve NS) and reduced the amount of edema present at 3 h by 82.1%, returning %BW nearly to the naïve value. %BW in the injury cohorts decreased towards levels of naïve rats at 6 h and 24 h post-CA (Figure 2b-c). Reference: Pediatr Res. 2019 Mar; 85(4): 511–517. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397683/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	125.0	269.60

Preparing Stock Solutions

The following data is based on the product molecular weight 463.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Wallisch JS, Janesko-Feldman K, Alexander H, Jha RM, Farr GW, McGuirk PR, Kline AE, Jackson TC, Pelletier MF, Clark RSB, Kochanek PM, Manole MD. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511-517. doi: 10.1038/s41390-018-0215-5. Epub 2018 Oct 26. PMID: 30367162; PMCID: PMC6397683.
In vitro protocol:	TBD
In vivo protocol:	1. Wallisch JS, Janesko-Feldman K, Alexander H, Jha RM, Farr GW, McGuirk PR, Kline AE, Jackson TC, Pelletier MF, Clark RSB, Kochanek PM, Manole MD. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511-517. doi: 10.1038/s41390-018-0215-5. Epub 2018 Oct 26. PMID: 30367162; PMCID: PMC6397683.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Wallisch JS, Janesko-Feldman K, Alexander H, Jha RM, Farr GW, McGuirk PR, Kline AE, Jackson TC, Pelletier MF, Clark RSB, Kochanek PM, Manole MD. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511-517. doi: 10.1038/s41390-018-0215-5. Epub 2018 Oct 26. PMID: 30367162; PMCID: PMC6397683.

2: Shangzu Z, Dingxiong X, ChengJun M, Yan C, Yangyang L, Zhiwei L, Ting Z, Zhiming M, Yiming Z, Liying Z, Yongqi L. Aquaporins: Important players in the cardiovascular pathophysiology. Pharmacol Res. 2022 Sep;183:106363. doi: 10.1016/j.phrs.2022.106363. Epub 2022 Jul 26. PMID: 35905892.

3: Kochanek PM, Bramlett HM, Dixon CE, Dietrich WD, Mondello S, Wang KKW, Hayes RL, Lafrenaye A, Povlishock JT, Tortella FC, Poloyac SM, Empey P, Shear DA. Operation Brain Trauma Therapy: 2016 Update. Mil Med. 2018 Mar 1;183(suppl_1):303-312. doi: 10.1093/milmed/usx184. PMID: 29635589.

4: Kochanek PM, Bramlett HM, Shear DA, Dixon CE, Mondello S, Dietrich WD, Hayes RL, Wang KK, Poloyac SM, Empey PE, Povlishock JT, Mountney A, Browning M, Deng- Bryant Y, Yan HQ, Jackson TC, Catania M, Glushakova O, Richieri SP, Tortella FC. Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. J Neurotrauma. 2016 Mar 15;33(6):606-14. doi: 10.1089/neu.2015.4133. PMID: 26671284.

5: Farr GW, Hall CH, Farr SM, Wade R, Detzel JM, Adams AG, Buch JM, Beahm DL, Flask CA, Xu K, LaManna JC, McGuirk PR, Boron WF, Pelletier MF. Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury. Neuroscience. 2019 Apr 15;404:484-498. doi: 10.1016/j.neuroscience.2019.01.034. Epub 2019 Feb 7. PMID: 30738082; PMCID: PMC6495193.

Your view history

AER-271 featured